Search

Zai Lab Ltd ADR

Geschlossen

BrancheGesundheitswesen

25.23 -0.9

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

24.66

Max

25.54

Schlüsselkennzahlen

By Trading Economics

Einkommen

191K

-51M

Verkäufe

6.7M

106M

EPS

-0.46

Gewinnspanne

-47.808

Angestellte

1,784

EBITDA

-2.1M

-46M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+54.48% upside

Dividenden

By Acuity

Nächstes Ergebnis

5. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

805M

2.9B

Vorheriger Eröffnungskurs

26.13

Vorheriger Schlusskurs

25.23

Nachrichtenstimmung

By Acuity

38%

62%

108 / 340 Ranking in Healthcare

Zai Lab Ltd ADR Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

1. Sept. 2026, 23:56 UTC

News

Wix.com Ltd faces a securities class action lawsuit over alleged false statements about its AI products, leading shares to trade lower in after-market hours.

1. Sept. 2026, 23:56 UTC

News

AbbVie Inc. has filed for a new Skyrizi regimen to treat Crohn's disease. Shares are lower in after-market hours amid broader market pressure from rising oil prices.

1. Sept. 2026, 23:51 UTC

News

Telephone and Data Systems withdraws Array Digital Infrastructure acquisition proposal and resumes share repurchase program. Shares rise in after-market trading.

1. Sept. 2026, 23:51 UTC

News
Correlated Moves

EOG Resources shares are higher after the company announced participation in the Barclays Energy-Power Conference, with oil prices surpassing $90 per barrel.

1. Sept. 2026, 23:46 UTC

News
Correlated Moves

Biontech SE's shares are lower in after-market hours following a decline in Moderna and amid ongoing challenges, including a halted cancer trial.

1. Sept. 2026, 23:46 UTC

News

Hormel Foods Corp will participate in the 2026 Barclays Global Consumer Staples Conference. Shares are trading higher during after-market hours following the announcement.

1. Sept. 2026, 23:41 UTC

News

StoneX Group Inc shares are lower in after-market hours, reflecting broader market concerns over rising oil prices and ongoing inflation fears amid recent negative trends.

1. Sept. 2026, 23:41 UTC

News

Carrier Global shares are higher in after-market trading ahead of the Morgan Stanley conference on September 15, 2026, featuring CEO David Gitlin.

1. Sept. 2026, 23:41 UTC

News
Correlated Moves

ONEOK Inc's shares are higher in after-market trading following several rating adjustments, including price target increases from Scotiabank and Morgan Stanley.

1. Sept. 2026, 23:41 UTC

News

Dropbox shares fell in after-market hours following a Bloomberg report on a data breach affecting about 5,000 user accounts.

1. Sept. 2026, 23:36 UTC

News

G-III Apparel Group has acquired the Marc Jacobs brand from LVMH. Shares are trading higher in after-market hours following the announcement.

1. Sept. 2026, 23:36 UTC

News

Quest Diagnostics has signed a multi-year agreement with Renalytix PLC for kidneyintelX.dkd testing, contributing to a modest rise in shares during after-market hours.

1. Sept. 2026, 23:31 UTC

News
Social Media

PBF Energy shares advanced in after-market trading following the release of its 2025 Sustainability Data Supplement, amid rising crude oil prices above $90.

1. Sept. 2026, 23:31 UTC

News
Correlated Moves
Social Media

Hong Kong's Exchange Fund fell to HK$4.404 trillion in July, with CAD/HKD trading lower amid rising crude oil prices and inflation concerns.

1. Sept. 2026, 23:26 UTC

News

Shareholders approve increase of authorized shares to 135 million.

1. Sept. 2026, 23:26 UTC

News

Tencent Music Entertainment shares are lower in after-market hours following a proposed public offering of senior unsecured notes for refinancing and share repurchases.

1. Sept. 2026, 23:21 UTC

News

Enovix Corp's drone battery portfolio is now TAA-compliant, boosting its U.S. defense supply chain position. Shares are lower in after-market trading amid broader market trends.

1. Sept. 2026, 23:21 UTC

News

Lamar Advertising Co declared a quarterly cash dividend of $1.65 per share, up from $1.60, as shares traded lower in after-market hours.

1. Sept. 2026, 23:16 UTC

News

BridgeBio Pharma shares are lower in after-market hours following a $500 million mixed securities shelf filing, raising concerns about potential dilution.

1. Sept. 2026, 23:16 UTC

News

Emerson Electric is trading higher in after-market hours following multiple analyst rating adjustments and price target changes from various firms.

1. Sept. 2026, 23:16 UTC

News

Adecoagro SA completed the R$705 million acquisition of Caarapó Mill, enhancing operations in Mato Grosso do Sul. Shares are trading higher after the announcement.

1. Sept. 2026, 23:16 UTC

News

ResMed Inc has initiated a $450 million accelerated share repurchase agreement, contributing to higher shares in after-market trading. Final settlement is set for December 2026.

1. Sept. 2026, 23:16 UTC

News

SoFi Technologies Inc shares rose in after-market hours following Scotiabank's initiation of coverage with a Sector Outperform rating and a price target of $25.00.

1. Sept. 2026, 23:16 UTC

News
Social Media

Palantir Technologies' subsidiary secured a prime contract with the Army for eight TITAN ground station systems, boosting shares slightly higher in after-hours trading.

1. Sept. 2026, 23:16 UTC

News
Correlated Moves
Social Media

CHF/HKD declines amid geopolitical tensions and a decrease in Hong Kong's Exchange Fund assets, which fell to HK$4.404 trillion at July's end.

1. Sept. 2026, 23:06 UTC

News
Social Media

Snowflake shares are higher in after-market trading as discussions on social media build ahead of its earnings report, with revenue expectations at $1.48 billion.

1. Sept. 2026, 23:06 UTC

News

Union Pacific shares are lower in after-market trading, amid rising oil prices and inflation concerns, despite updates on its merger with Norfolk Southern.

1. Sept. 2026, 23:06 UTC

News

Sprouts Farmers Market shares fell in after-hours trading following the announcement of a leadership transition, with Nick Konat set to become CEO in January 2027.

1. Sept. 2026, 23:06 UTC

News
Correlated Moves
Social Media

The USD/DKK is trading higher as rising oil prices raise inflation concerns amid geopolitical tensions in the Middle East.

1. Sept. 2026, 23:06 UTC

News
Social Media

Alphabet Inc. shares rose in after-hours trading on positive sentiment surrounding its upcoming AI model, Gemini 3.8 Flash, expected to enhance coding capabilities.

Peer-Vergleich

Kursveränderung

Zai Lab Ltd ADR Prognose

Kursziel

By TipRanks

54.48% Vorteil

12-Monats-Prognose

Durchschnitt 39.33 USD  54.48%

Hoch 45 USD

Tief 36 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Zai Lab Ltd ADR – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

3 ratings

3

Buy

0

Halten

0

Sell

Stimmung

By Acuity

108 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat